Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy.

Elsahwi KS, Santin AD.

Obstet Gynecol Int. 2011;2011:128295. doi: 10.1155/2011/128295. Epub 2011 Aug 11.

2.

Gynecologic Cancer InterGroup (GCIG) consensus review for uterine serous carcinoma.

Sagae S, Susumu N, Viswanathan AN, Aoki D, Backes FJ, Provencher DM, Vaughan M, Creutzberg CL, Kurzeder C, Kristensen G, Lee C, Kurtz JE, Glasspool RM, Small W Jr.

Int J Gynecol Cancer. 2014 Nov;24(9 Suppl 3):S83-9. doi: 10.1097/IGC.0000000000000264. Review.

PMID:
25341586
3.

Current treatment options for endometrial cancer.

Santin AD, Bellone S, O'Brien TJ, Pecorelli S, Cannon MJ, Roman JJ.

Expert Rev Anticancer Ther. 2004 Aug;4(4):679-89. Review.

PMID:
15270671
4.

Overview of resistance to systemic therapy in patients with breast cancer.

Gonzalez-Angulo AM, Morales-Vasquez F, Hortobagyi GN.

Adv Exp Med Biol. 2007;608:1-22. Review.

PMID:
17993229
5.

Minimal uterine serous carcinoma: current concepts in diagnosis and prognosis.

Rabban JT, Zaloudek CJ.

Pathology. 2007 Feb;39(1):125-33. Review.

PMID:
17365828
6.

Early stage uterine serous carcinoma: management updates and genomic advances.

Fader AN, Santin AD, Gehrig PA.

Gynecol Oncol. 2013 Apr;129(1):244-50. doi: 10.1016/j.ygyno.2013.01.004. Epub 2013 Jan 12. Review.

PMID:
23321062
7.

Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer.

El-Sahwi KS, Schwartz PE, Santin AD.

Expert Rev Anticancer Ther. 2012 Jan;12(1):41-9. doi: 10.1586/era.11.192. Review.

8.

The curability of breast cancer and the treatment of advanced disease.

Guarneri V, Conte PF.

Eur J Nucl Med Mol Imaging. 2004 Jun;31 Suppl 1:S149-61. Epub 2004 Apr 24. Review.

PMID:
15107948
9.

Predicting the efficacy of trastuzumab-based therapy in breast cancer: current standards and future strategies.

Singer CF, Köstler WJ, Hudelist G.

Biochim Biophys Acta. 2008 Dec;1786(2):105-13. doi: 10.1016/j.bbcan.2008.02.003. Epub 2008 Mar 4. Review.

PMID:
18375208
10.

Molecular alterations in uterine serous carcinoma.

Hayes MP, Ellenson LH.

Gynecol Oncol. 2010 Feb;116(2):286-9. doi: 10.1016/j.ygyno.2009.11.012. Review.

PMID:
20109727
11.

The role of trastuzumab in early stage breast cancer: current data and treatment recommendations.

Lin A, Rugo HS.

Curr Treat Options Oncol. 2007 Feb;8(1):47-60. Review.

PMID:
17660958
12.

Management of ErbB2-positive breast cancer: insights from preclinical and clinical studies with lapatinib.

Vogel C, Chan A, Gril B, Kim SB, Kurebayashi J, Liu L, Lu YS, Moon H.

Jpn J Clin Oncol. 2010 Nov;40(11):999-1013. doi: 10.1093/jjco/hyq084. Epub 2010 Jun 11. Review.

14.

Linking uterine serous carcinoma to BRCA1/2-associated cancer syndrome: A meta-analysis and case report.

de Jonge MM, Mooyaart AL, Vreeswijk MP, de Kroon CD, van Wezel T, van Asperen CJ, Smit VT, Dekkers OM, Bosse T.

Eur J Cancer. 2017 Feb;72:215-225. doi: 10.1016/j.ejca.2016.11.028. Epub 2016 Dec 31. Review.

PMID:
28049106
15.

The development and clinical use of trastuzumab (Herceptin).

Harries M, Smith I.

Endocr Relat Cancer. 2002 Jun;9(2):75-85. Review.

16.

Treatment of breast cancer.

Maughan KL, Lutterbie MA, Ham PS.

Am Fam Physician. 2010 Jun 1;81(11):1339-46. Review.

17.

Cardiac toxicity of ErbB2-targeted therapies: what do we know?

Perez EA.

Clin Breast Cancer. 2008 Mar;8 Suppl 3:S114-20. Review.

PMID:
18777950

Supplemental Content

Support Center